OSE Immunotherapeutics has teamed up with Memorial Sloan Kettering Cancer Center to work on its anti-CD127 antibody OSE-703.

​​​​​​​Celgene has landed an option on four natural killer cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics.

Helomics is partnering with Pittsburgh Life Sciences Greenhouse to establish an incubator for diagnostics and precision medicine.

Array claims $31.6 million upfront from Ono for rights to binimetinib and encorafenib in Japan and South Korea, adding to its deal with Pierre Fabre in Europe.

AstraZeneca has paid $45 million and committed to up to $2.1 billion in milestones to team with Pieris Pharmaceuticals.

CureVac has hired Daniel Menichella as CEO of its Boston-based subsidiary and tasked him with striking deals.

Takeda Pharmaceutical has teamed up with Harrington Discovery Institute to support research into treatments for rare diseases.

Shares in U.K. biotech Synairgen were pummeled today as partner AstraZeneca revealed it was stopping development of its inhaled interferon beta therapy AZD9412.

Novartis will play a bigger role in the marketing of Amgen's migraine drug erenumab, and analysts say the move may reflect reduced sales expectations.